

**CIRM Scientific and Medical Research Funding Working Group:  
Biographical information of candidates nominated to serve as  
Alternate Scientific Members of the Working Group**

**1. Andrew E. Balber, PhD**

Andrew E. Balber is a Founder and the Chief Scientific Officer at Aldagen, Inc., a Durham, NC company developing adult stem cell therapy products for use in transplantation and tissue repair. Dr. Balber received his BA in biology from Haverford College, in Haverford, PA and his Ph.D. from the Rockefeller University in New York. He carried out his post-doctoral research at the Yale University School of Medicine.

Dr. Balber began his work in cell therapies in 1983 as a Duke University faculty member in immunology and Director of the Comprehensive Cancer Center Flow Cytometry Facility. At Duke, he helped organize and manage a university-based, industry sponsored research consortium in immunology, which successfully developed several technologies for the isolation, propagation and commercial use of T- and B-lymphocyte populations and monoclonal antibodies. In the area of cell therapies, Dr. Balber was centrally involved in the establishment of Merix Bioscience, now Argos Therapeutics, and also in the establishment of a manufacturing facility used collaboratively by Applied Immune Sciences and Duke to produce cellular therapeutics. As CSO of Aldagen, Dr. Balber has helped establish a clinical program with four cell therapy products in clinical trials, including one Phase 3 clinical candidate. In addition, he has helped the company launch a research-use-only product for identifying stem and progenitor cells, and obtained FDA clearance to market a second product for clinical enumeration of these cells.

**2. Richard P Harvey, PhD FAA**

Professor Richard Harvey, PhD, FAA (Australia), is the Co-Deputy Director and Head of the Developmental Biology Division at the Victor Chang Cardiac Research Institute (VCCRI) in Sydney Australia. Dr. Harvey received his PhD in Molecular Biology under supervision of the late JRE Wells from the Department of Biochemistry, University of Adelaide.

Dr. Harvey's research interests include cardiac developmental biology and stem cells. He holds the endowed Sir Peter Finley Professorship of Cardiac Research at the University of New South Wales and is a Research Project Director of the Australian Stem Cell Centre. In 2001, he received the Hazel Croke Research Award from the NHF; in 2004, the RT Hall Prize, the highest senior investigator award of the Cardiac Society of Australia and New Zealand; in 2005, the Julian Wells Medal and Oration, conferred by the Executive Committee of the Lorne Genome Meeting; and in 2007 the Evelyn Hall Award of the National Heart Foundation. In 2007 he was elected member of the Australian Academy of Science. He is on the editorial boards of *Developmental Cell*, *Developmental Biology*, *Developmental Dynamics*, *Trends in Cardiovascular Medicine* and *Stem Cell Research*.

### **3. C. Randal Mills, PhD**

Dr. C. Randal Mills serves as President and Chief Executive Officer of Osiris Therapeutics, which he joined in 2004. Dr. Mills holds a BS in microbiology and cell science and a PhD in pharmaceutical science and drug development from the University of Florida.

Dr. Mills' corporate accomplishments include taking Osiris public in 2006; forming a \$1.38 billion partnership with Genzyme Corporation for the commercialization of stem cell products; receiving a \$224.7 million award from the United States Department of Defense; and launching the world's first stem cell product, Osteocel®. Prior to joining Osiris, Dr. Mills was an executive officer and founding member of Regeneration Technologies, Inc. (NASDAQ—RTIX). He currently serves on the Board of Directors for Osiris Therapeutics, Tissue Banks International, and the Technology Council of Maryland.

### **4. Steven D. Sheridan, PhD**

Dr. Steven Sheridan is the Principal Scientist for Millipore Corporation's Stem Cells and Cell Biology Group. He received his PhD in Molecular Biology and Genetics from the University of California Irvine, and was a post-doctoral fellow in the laboratory of James C. Wang, at Harvard University.

At Millipore Corporation, Dr. Sheridan develops and supports new research and development programs for cell biology research. He serves as an internal and external expert on technology development for both basic and applied research as well as screening platforms. He also develops and resources strategic plans for divisional stem cells and cell biology research and development segments. Dr. Sheridan leads two cross-functional matrixed development teams in focused research areas toward strategic planning, resourcing and implementation. He has successfully established collaborations with major pharmaceutical and biotechnology partners in various molecular and cell based assays and technologies as well as developed and coordinated external collaborations with academic and industrial researchers. Previously, Dr. Sheridan was Group Leader of Millipore's Molecular and Cell Based Assay Development Group, where he directed assay development in areas including cellular expansion and differentiation, signal transduction, proliferation, and marker analysis. His expertise also includes molecular assay development in drug discovery platforms for receptor ligand binding (GPCR, Nuclear Hormone) and kinase assays. Prior to joining Millipore, Dr. Sheridan worked at Cythera where his research involved using molecular, cellular and stem cell biological techniques to differentiate murine and human embryonic stem cells into insulin producing cells during *in-vitro* differentiation for the intended goal of supplementing the supply of such cells for diabetic patients.